Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
作者信息
McComb Janet M, Camm A John
出版信息
BMJ. 2002 Nov 9;325(7372):1050-1. doi: 10.1136/bmj.325.7372.1050.
Abstract
摘要
相似文献
1
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.使用植入式心脏复律除颤器进行心脏性猝死的一级预防。
BMJ. 2002 Nov 9;325(7372):1050-1. doi: 10.1136/bmj.325.7372.1050.
2
Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.以胺碘酮为校准剂的塞利伐酮在植入式心脏复律除颤器患者中预防植入式心脏复律除颤器干预或死亡的疗效和安全性：ALPHEE 研究。
Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14.
3
Wide QRS, narrow QRS: what's the difference?宽QRS波、窄QRS波：有何区别？
J Am Coll Cardiol. 2005 Jul 19;46(2):317-9. doi: 10.1016/j.jacc.2005.04.021.
4
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.植入式心脏复律除颤器对肥厚型心肌病患者预防猝死的疗效。
N Engl J Med. 2000 Feb 10;342(6):365-73. doi: 10.1056/NEJM200002103420601.
5
The nature of the game.
J Cardiovasc Electrophysiol. 2005 May;16(5):483-5. doi: 10.1111/j.1540-8167.2005.40853.x.
6
Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.植入型心律转复除颤器在伴心脏传导障碍的核纤层蛋白 A/C 突变携带者中的应用。
Heart Rhythm. 2013 Oct;10(10):1492-8. doi: 10.1016/j.hrthm.2013.06.020. Epub 2013 Jun 26.
7
[Updated ESC guideline: innovations for the treatment of ventricular arrhythmias and recommendations for prevention of sudden cardiac death].[更新的欧洲心脏病学会指南：室性心律失常治疗的创新及心脏性猝死预防建议]
Herzschrittmacherther Elektrophysiol. 2016 Sep;27(3):288-94. doi: 10.1007/s00399-016-0446-2.
8
Wearable cardioverter-defibrillators.可穿戴式心脏复律除颤器
Circulation. 2013 Feb 19;127(7):854-60. doi: 10.1161/CIRCULATIONAHA.112.146530.
9
Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.植入式心脏复律除颤器对晚期心力衰竭女性心脏性猝死一级预防的有效性：一项随机对照试验的荟萃分析。
Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255.
10
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials.美国心力衰竭学会/美国心脏病学会/美国心脏协会关于在临床试验中未纳入或代表性不足的患者中使用植入式心脏复律除颤器治疗的专家共识声明
Circulation. 2014 Jul 1;130(1):94-125. doi: 10.1161/CIR.0000000000000056. Epub 2014 May 9.
本文引用的文献
1
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.对心肌梗死且射血分数降低的患者进行预防性植入除颤器。
N Engl J Med. 2002 Mar 21;346(12):877-83. doi: 10.1056/NEJMoa013474. Epub 2002 Mar 19.
2
Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology.植入式心脏复律除颤器（ICD）治疗的适应症。欧洲心脏病学会心律失常工作组和心脏起搏工作组ICD指南研究组。
Eur Heart J. 2001 Jul;22(13):1074-81. doi: 10.1053/euhj.2001.2584.
3
Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers.
J Am Coll Cardiol. 2001 Jun 1;37(7):1901-7. doi: 10.1016/s0735-1097(01)01246-3.
4
Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators.通过电生理测试来识别有冠心病猝死风险的患者。多中心非持续性心动过速试验研究者。
N Engl J Med. 2000 Jun 29;342(26):1937-45. doi: 10.1056/NEJM200006293422602.
5
A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.一项关于冠心病患者猝死预防的随机研究。多中心非持续性心动过速试验研究人员。
N Engl J Med. 1999 Dec 16;341(25):1882-90. doi: 10.1056/NEJM199912163412503.
6
Evidence-based analysis of amiodarone efficacy and safety.胺碘酮疗效与安全性的循证分析。
Circulation. 1999 Nov 9;100(19):2025-34. doi: 10.1161/01.cir.100.19.2025.
7
Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era.溶栓时代心肌梗死后非持续性室性心动过速的长期随访患病率、特征及预后价值
J Am Coll Cardiol. 1999 Jun;33(7):1895-902. doi: 10.1016/s0735-1097(99)00108-4.
8
Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial.
Am J Cardiol. 1998 Sep 1;82(5):683-5, A8. doi: 10.1016/s0002-9149(98)00417-2.
9
ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation).美国心脏病学会/美国心脏协会心脏起搏器与抗心律失常器械植入指南：美国心脏病学会/美国心脏协会实践指南工作组（起搏器植入委员会）报告
J Am Coll Cardiol. 1998 Apr;31(5):1175-209. doi: 10.1016/s0735-1097(98)00024-2.
10
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.植入式除颤器可提高冠心病合并室性心律失常高危患者的生存率。多中心自动除颤器植入试验研究者。
N Engl J Med. 1996 Dec 26;335(26):1933-40. doi: 10.1056/NEJM199612263352601.
Zotero 插件